Success stories
The introduction of tyrosine kinase inhibitors (TKI) has enabled patients with Chronic Myeloid Leukemia (CML) to reach a similar survival to that of the general population. However, some patients do not benefit from the effectiveness of TKI, mainly due to resistance or side effects. This study, conducted on a national scale in France with over 500 patients using the French healthcare database system (Système National des Données de Santé (SNDS)), documents the long-term TKI treatment patterns (successive lines). The results show that nearly 20% of patients have initiated at least three lines of TKIs, corresponding to patients whose therapeutic needs are not currently met.
This study, which is the subject of an oral presentation at the ASH (American Society of Hematology) 2023 congress, demonstrates the value of SNDS for reconstructing real-life therapeutic strategies.
N° T40786692021052 (https://www.health-data-hub.fr/projets/real-life-treatment-patterns-and-burden-illness-among-patients-chronic-myeloid-leukemia-cml)
Data Controller: Novartis
Data Processor: RCTs
Scientific Committee: Franck-Emmanuel Nicolini
https://ashpublications.org/blood/article/142/Supplement%201/3174/500013/Tyrosine-Kinase-Inhibitor-TKI-Treatment-Patterns
